

Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache

NCT03781128

Status	RECRUITING
Phase	Phase 2
Sponsor	University Hospital, Basel, Switzerland
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (10)

- Age e 25 and d 75 years
- Chronic cluster headache (according to the International Headache Society (IHS) criteria) OR
- Episodic cluster headache (according to the IHS criteria) with recurrent predictable episodes lasting approximately 2 months and expected ongoing cluster period for at least one month beyond the inclusion
- Attacks respond to oxygen
- Sufficient understanding of the study procedures and risks associated with the study

... and 5 more (see full listing online)

Exclusion (11)

- Other forms of headache attacks (migraine, paroxysmal hemicranias, shortlasting unilateral neuralgiform headache attacks with conjunctival injection, tearing, sweating and rhinorrhea (SUNCT) or with cranial autonomic symptoms (SUNA))
- Women who are pregnant, nursing or of child-bearing potential and are not practicing an effective means of birth control (double-barrier method, i.e. pill/intrauterine device and preservative/diaphragm)
- Past or present diagnosis of a primary psychotic disorder. Subjects with a first degree relative with psychotic disorders are also excluded.
- Past or present bipolar disorder (DSM-IV).
- Current substance use disorder (within the last 2 months, DSM-V, except nicotine).

... and 6 more (see full listing online)

Locations (1 total)

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland